Aldeyra Therapeutics, Inc.
reproxalap
dry eye disease
Resolved
461days ago
FDA decision · Apr 2, 2025
What's at stake
The FDA's approval decision on reproxalap for dry eye disease is due Apr 2, 2025. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“In November 2024, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of April 2, 2025.”